延长释放维洛克萨与阿托莫克赛丁相比,用于注意力缺陷过度活动障碍
Maxwell Z Price1, Richard L Price2
1Hackensack Meridian School of Medicine, Nutley, NJ, 07110, USA. mzp2103@columbia.edu.
患有综合性多动症的患者表现出显著的症状改善,从阿托莫克赛丁切换到维洛克萨ER (VER). 在儿童和成年ADHD患者中,VER在注意力不集中和过度活跃/冲动性方面表现出更高的有效性和耐受性.
科学领域:
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
背景情况:
- 精神兴奋剂和α-2激动剂是常见的ADHD治疗方法,但具有局限性.
- 亚托莫克西丁和维洛克萨辛ER (VER) 用于联合ADHD,但保险公司通常首先要求进行亚托莫克西丁试验.
- 这项研究解决了评估VER的必要性,作为联合多动症治疗中阿托莫克赛丁的替代品.
研究的目的:
- 为了确定儿童和成人患者与ADHD综合体验症状改善,从阿托莫克赛丁切换到VER后.
- 为了比较VER与atomoxetine在治疗ADHD症状中的有效性和耐受性.
主要方法:
- 进行了一项对50名儿童和成人患者的回顾性评估,这些患者患有综合多动症和多动症.
- 患者从阿托莫克赛丁转换为灵活定位的VER在洗期后.
- 在治疗前和治疗后使用ADHD-RS-5和AISRS尺度评估ADHD症状.
主要成果:
- 与阿托莫克赛丁相比,患者在VER的注意力和过度活跃/冲动性都显著改善.
- 86%的患者在2周内报告了对VER的积极反应,而14%的患者接受了atomoxetine.
- 由于副作用,VER的耐受性更好,仅有4%的患者因副作用而停药,而阿托莫克赛丁的这一比例为36%.
结论:
- 延长释放的维洛克萨 (VER) 能够在组合型ADHD患者中快速改善ADHD症状.
- 在这个患者群体中,与阿托莫克赛丁相比,VER显示出更高的疗效和耐受性.
- 对于那些对阿托莫克赛丁有不充分的反应或不耐受症的综合多动症患者来说,VER可能是一个有价值的替代品.
更多相关视频
05:48The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
Published on: June 12, 2020
13:09Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol
Published on: April 1, 2018
相关概念视频
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Antidepressant Drugs: MAOIs and Other Agents
Antidepressant Drugs: Overview
Anxiolytic Drugs: Overview
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic...
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
